

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Dantanarayana et al.

U.S. Serial No. 10/580,528

Confirmation No: 4326

Filed: May 24, 2006

Examiner: N. Westerberg

Group Art Unit: 1618

For: **SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE
TREATMENT OF GLAUCOMA**

CERTIFICATE OF FILING VIA EFS-WEB

I hereby certify that this correspondence is being submitted to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA. 22313-1450 via EFS-Web on this Date:

June 30, 2008

By: /Jeannie Burke/
Jeannie Burke

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. §1.97 (c) and FEE PURSUANT TO 37C.F.R. § 1.17 (p)**

MS Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. § 1.97(c), Applicants submit the attached PTO Form 1449. Neither a final Office Action under §1.113 nor a notice of allowance under §1.311 have been issued in the above-referenced application.

Because the PTO has waived the requirement under 37 CFR 1.98(a)(2) to submit copies of each cited U.S. patent and patent application publication in all U.S. national patent applications filed after June 30, 2003, none are enclosed. Only copies of cited foreign patent documents and non-patent literature are enclosed.

Please charge Deposit Account No. 501051 the requisite fee under 37 C.F.R. §1.17(p).

Applicants request that the listed references be considered during prosecution of this application, and that the references appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

ALCON

June 30, 2008

/Patrick M. Ryan/

Patrick M. Ryan

Registration No. 36,263

Alcon Research, Ltd.
IP Legal TB4-8
6201 South Freeway
Fort Worth, Texas 76134-2099
(817) 551-3066

Attorney Docket No.: 2514